EA201201416A1 - Соединение для лечения состояния или заболевания органов дыхания - Google Patents

Соединение для лечения состояния или заболевания органов дыхания

Info

Publication number
EA201201416A1
EA201201416A1 EA201201416A EA201201416A EA201201416A1 EA 201201416 A1 EA201201416 A1 EA 201201416A1 EA 201201416 A EA201201416 A EA 201201416A EA 201201416 A EA201201416 A EA 201201416A EA 201201416 A1 EA201201416 A1 EA 201201416A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
disease
condition
connection
respiratory system
Prior art date
Application number
EA201201416A
Other languages
English (en)
Other versions
EA025224B1 (ru
Inventor
Джон Николас Ламберт
Джейн Райан
Джанет Мари Уилсон
Original Assignee
Байота Сайентифик Менеджмент Пти Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010901601A external-priority patent/AU2010901601A0/en
Application filed by Байота Сайентифик Менеджмент Пти Лтд. filed Critical Байота Сайентифик Менеджмент Пти Лтд.
Publication of EA201201416A1 publication Critical patent/EA201201416A1/ru
Publication of EA025224B1 publication Critical patent/EA025224B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к лечению, облегчению, предупреждению или уменьшению симптомов обострения астмы или хронического обструктивного заболевания легких (COPD), типичным клиническим проявлением которых обычно служит сниженная функция легких.
EA201201416A 2010-04-15 2011-04-14 ПРИМЕНЕНИЕ 3-ЭТОКСИ-6-{2-[1-(6-МЕТИЛПИРИДАЗИН-3-ИЛ)ПИПЕРИДИН-4-ИЛ]ЭТОКСИ}БЕНЗО[d]ИЗОКСАЗОЛА ИЛИ ЕГО ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМОЙ СОЛИ ПРИ ЛЕЧЕНИИ ИЛИ ОБЛЕГЧЕНИИ СИМПТОМОВ АСТМЫ EA025224B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2010901601A AU2010901601A0 (en) 2010-04-15 Compound for the treatment of respiratory condition or disease
PCT/AU2011/000434 WO2011127538A1 (en) 2010-04-15 2011-04-14 Compound for treatment of respiratory condition or disease

Publications (2)

Publication Number Publication Date
EA201201416A1 true EA201201416A1 (ru) 2013-03-29
EA025224B1 EA025224B1 (ru) 2016-12-30

Family

ID=44788654

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201416A EA025224B1 (ru) 2010-04-15 2011-04-14 ПРИМЕНЕНИЕ 3-ЭТОКСИ-6-{2-[1-(6-МЕТИЛПИРИДАЗИН-3-ИЛ)ПИПЕРИДИН-4-ИЛ]ЭТОКСИ}БЕНЗО[d]ИЗОКСАЗОЛА ИЛИ ЕГО ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМОЙ СОЛИ ПРИ ЛЕЧЕНИИ ИЛИ ОБЛЕГЧЕНИИ СИМПТОМОВ АСТМЫ

Country Status (16)

Country Link
US (1) US20110257192A1 (ru)
EP (1) EP2558097B1 (ru)
JP (1) JP6148618B2 (ru)
KR (1) KR20130106267A (ru)
CN (2) CN102844032A (ru)
AU (1) AU2011241478B2 (ru)
BR (1) BR112012026244A2 (ru)
CA (1) CA2796207A1 (ru)
EA (1) EA025224B1 (ru)
ES (1) ES2647223T3 (ru)
IL (1) IL222244A0 (ru)
MX (1) MX2012011938A (ru)
NZ (1) NZ603040A (ru)
SG (2) SG184430A1 (ru)
WO (1) WO2011127538A1 (ru)
ZA (1) ZA201207696B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9815814B2 (en) 2013-04-12 2017-11-14 Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises” Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
CA2952627C (en) * 2014-06-20 2018-05-22 Aviragen Therapeutics, Inc. Anhydrous crystalline free base form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR213700A0 (en) * 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
US20060167109A1 (en) * 2002-02-14 2006-07-27 Pevear Daniel C Methods of reducing rhinovirus contagion and related compositions
EP1596859B1 (en) * 2003-02-21 2008-07-02 Apodemus AB Treatment of diseases caused by ljungan virus by using pleconaril
US9308199B2 (en) * 2004-04-29 2016-04-12 Honeywell International Inc. Medicament formulations
US20060069124A1 (en) * 2004-09-07 2006-03-30 Rao P S Use of MDL-100,907 for treatment of allergic and eosinophil mediated diseases
AR057623A1 (es) * 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
WO2009143571A1 (en) * 2008-05-27 2009-12-03 Biota Scientific Management Pty Ltd Antiviral salts
TW201016215A (en) * 2008-07-17 2010-05-01 Schering Corp Compositions and uses of antiviral active pharmaceutical agents

Also Published As

Publication number Publication date
ZA201207696B (en) 2014-03-26
CA2796207A1 (en) 2011-10-20
SG184430A1 (en) 2012-11-29
US20110257192A1 (en) 2011-10-20
JP2013523844A (ja) 2013-06-17
JP6148618B2 (ja) 2017-06-14
WO2011127538A1 (en) 2011-10-20
AU2011241478A1 (en) 2012-11-01
EP2558097A4 (en) 2013-09-11
EP2558097A1 (en) 2013-02-20
NZ603040A (en) 2015-03-27
EP2558097B1 (en) 2017-10-25
BR112012026244A2 (pt) 2016-07-12
KR20130106267A (ko) 2013-09-27
IL222244A0 (en) 2012-12-31
MX2012011938A (es) 2013-01-28
CN102844032A (zh) 2012-12-26
EA025224B1 (ru) 2016-12-30
AU2011241478B2 (en) 2016-12-01
ES2647223T3 (es) 2017-12-20
SG10201502391WA (en) 2015-05-28
CN105560245A (zh) 2016-05-11

Similar Documents

Publication Publication Date Title
EA201190108A1 (ru) Фармацевтическая композиция для ингаляции
WO2012110770A3 (en) Combination of glycopyrrolate and a beta2 -agonist
EA201200876A1 (ru) Новые антагонисты рецептора ccr2 и их применение
EA201400591A1 (ru) Ингалятор
WO2012103216A3 (en) Apparatus and methods for assisting breathing
GEP20186885B (en) Novel compounds
CL2014000122A1 (es) Compuestos derivados de indazol, inhibidores de janus quinasa (jak); composicion farmaceutica que los comprende; y su uso para tratar rinitis alergica, congestion nasal, asma, bronquitis cronica, artritis, insuficiencia cardiaca, colitis ulcerativa, infeccion viral y bacteriana, cancer y alzheimer, entre otras enfermedades.
BR112015012312A2 (pt) método de tratamento, redução do risco, prevenção ou alívio de uma afecção ou doença pulmonar em um sujeito; método de redução ou supressão de inflamação no pulmão em um sujeito; e método de promoção de reparo pulmonar em um sujeito
CL2008001593A1 (es) Compuestos derivados de heterociclos, antagonistas para el ccr2; y uso de los compuestos para tratar afecciones o enfermedades del tracto respiratorio, como enfermedad pulmonar obstructiva cronica y asma.
WO2010094720A3 (en) Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
UY31686A1 (es) Nueva dosificacion y formulacion
EA201690335A1 (ru) Новые средства для уменьшения негативных последствий курения
UY31687A1 (es) Nueva dosificacion y formulacion
MY174877A (en) Anti-adrenomedullin (adm) antibpdy or anti-adm antibody fragment of anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic of acute disease or acute condition
EP3675719A4 (en) USE OF INHALED NITRIC OXIDE FOR THE TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH PULMONARY DISORDER
GB2496800A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
WO2011021203A3 (en) Desferrioxamine-metal complexes for the treatment of immune-related disorders
EA201201395A1 (ru) Кнопочное устройство мундштука ингалятора сухого порошка
EP2585067A4 (en) COMPOUND FOR THE TREATMENT OF ENTEROVIRUS
WO2015023508A8 (en) Methods for improving asthma symptoms using benralizumab
MX2019013468A (es) Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab.
WO2013095091A3 (en) Rsv g protein specific antibodies
EA201201416A1 (ru) Соединение для лечения состояния или заболевания органов дыхания
TR201905319T4 (tr) Nevralji, ağrı, KOAH (Kronik, Obstruktif Akciğer Hastalığı) ve astım tedavisinde TRPM8-inhibitörleri olarak yararlı 2-aril-4-hidroksi-1,3-tiyazol türevleri.
UA115989C2 (uk) Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU